Open Lab as a source of hits and leads against tuberculosis, malaria and kinetoplastid diseases

Nature Reviews Drug Discovery

Volumn 15, Issue 4, 2016, Pages 292-

  Ballell, Lluís ^a   Strange, Mike ^a   Cammack, Nicholas ^a   Fairlamb, Alan H ^a   Borysiewicz, Leszek ^b  

^a GLAXOSMITHKLINE   (Spain)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTITRYPANOSOMAL AGENT; CLAVULANIC ACID; MEROPENEM; MEROPENEM PLUS CLAVULANATE; TAFENOQUINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ACCREDITATION; CONCEPTUAL FRAMEWORK; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; HUMAN; INFORMATION DISSEMINATION; KNOWLEDGE; LETTER; MALARIA; MEDICAL INFORMATION; MINIMUM INHIBITORY CONCENTRATION; PATENT; PRIORITY JOURNAL; PROTEOMICS; TRYPANOSOMATID INFECTION; TUBERCULOSIS; ANIMAL; DEVELOPING COUNTRY; DRUG DEVELOPMENT; NEGLECTED DISEASES; NON PROFIT ORGANIZATION; TRENDS;

ANIMALS; DEVELOPING COUNTRIES; DRUG DISCOVERY; FOUNDATIONS; HUMANS; MALARIA; NEGLECTED DISEASES; TUBERCULOSIS;

EID: 84961763041     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2016.51     Document Type: Letter

References (10)

1. Katsuno, K. et al. Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nat. Rev. Drug Discov. 14, 751-758 (2015).
2. Gamo, F. J. et al. Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305-310 (2010).
3. Ballell, L. et al. Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. ChemMedChem. 8, 313-321 (2013).
4. Peña, I. et al. New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: An open resource. Sci. Rep. 5, 8771 (2015).
5. Almela, M. J. et al. A new set of chemical starting points with Plasmodium falciparum transmission-blocking potential for antimalarial drug discovery. PLoS ONE. 10, e0135139 (2015).
6. Younis, Y. et al. 3,5-diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J. Med. Chem. 55, 3479-3487 (2012).
7. Phillips, M. A. et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci. Transl Med. 55, 296ra111 (2015).
8. Cox, J. A. G. et al. THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria. Nat. Microbiol. 1, 15006 (2016).
9. Ghidelli-Disse, S. et al. Identification of Plasmodium PI4 kinase as target of MMV390048 by chemoproteomics. Malar. J. 13 (Suppl. 1), P38 (2014).
10. Abrahams, K. A. et al. Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS ONE. 7, e52951 (2012).